AVBPライブシグナル | Getagraph.comで利益を最大化

買う 136734 min ago

@ $21.16

発行日: 15 2月 2024 @ 05:35

リターン: -5.01%

前回のシグナル: 2月 14 - 03:28

前回のシグナル: 売る

リターン: -2.49 %

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Stats
本日の出来高	63 766.00
平均出来高	170 933
時価総額	673.23M
次の収益日	( $-0.580 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0870 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	555 555	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	313 076	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Buy	3 616 041	Common Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	4 761 903	Series B Preferred Stock
2024-01-30	Hillhouse Investment Management, Ltd.	Sell	55 000 000	Series A Preferred Stock

INSIDER POWER
-74.77
Last 24 transactions
Buy: 9 226 636 \| Sell: 63 909 387

ボリューム相関

長: 0.21 (neutral)

短: 0.97 (very strong)

Signal:(46.723) Expect same movement, but be aware

ArriVent BioPharma, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ArriVent BioPharma, Inc. 相関 - 通貨/商品

-0.23
( neutral )

0.03
( neutral )

-0.17
( neutral )

-0.11
( neutral )

-0.64
( weak negative )

0.24
( neutral )

Financial Reports:

No articles found.

ArriVent BioPharma, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.